Slide 1: Immuron CEO presentation to Coffee Microcaps Conference
Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Melbourne, Australia, March 7, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Coffee Microcaps Conference on Friday 7th Mar
Slide 2: Platform technology, IMM-124E and IMM-529 background
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: IBS background and references
Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected.
Slide 4: Coffee Microcaps
NASDAQ: IMRN ASX: IMC For personal use only Coffee Microcaps Steven Lydeamore Chief Executive Officer 7 March 2025
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Immuron Limited
Immuron Limited Vancouver, BC Immuron Ltd is an Australian integrated biopharmaceutical company with global Canada scale, focused on developing, and commercialising, oral immunotherapeutic for the For personal use only treatment of gut mediated diseases Immuron Inc New York USA Technology Research &
Slide 8: Travellers' Diarrhoea: Facts
TRAVELLERS DIARRHOEA: FACTS For personal use only Travellers’ Diarrhoea – What is it? • Travellers’ Diarrhoea is more commonly referred to as Bali Belly, Delhi Belly, Montezuma’s Revenge, Tourist Trot, Rangoon Runs or just TD. • Characterised by fever, belly cramps and profuse watery diarrhoea that
Slide 9: Travel statistics
Travel statistics: For personal use only • Statistics show that diarrhea and symptoms associated with gastrointestinal disorders is one of the leading travel health problems, affecting up to 70% of travelers (in medium to high risk area’s) • Travellers Diarrhoea frequently occurs in environments whe
Slide 10: Opportunity to Convert Billion Dollar Traveller's Diarrhoea Market
Opportunity to Convert Billion Dollar Traveller’s Diarrhoea Market from Relief to Prevention by Travelan® Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7%1 For personal use only Industry tailwinds International travel continues to grow Travel to high
Slide 11: Continued Strong Sales Growth
CONTINUED STRONG SALES GROWTH For personal use only o Global sales increased by 172% in the 2024 fiscal year to a record o USA A$4.9 million compared to A$1.8 million in FY23 o FY24: a record A$1.08 million; up 67% o Half Yearly sales record in Dec 24 A$4.0 million, up 70% pcp o Half Yearly sales in
Slide 12: Expansion of Travelan Distribution
EXPANSION OF TRAVELAN® DISTRIBUTION For personal use only
Slide 13: Strong Pipeline with Near Term Milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES Peak U.S. Current Indication Compound Preclinical Phase 1 Phase 2 Phase 3 Registration Collaborator 1H 2025 2H 2025 sales Status For personal use only Uniformed 100% of 866 Recruitment Traveller's Diarrhoea Travelan® US$ 102 m Services participants Topline D
Slide 14: Scientific references
Scientific references Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC- For personal use only Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Slide 15: Steven Lydeamore, Chief Executive Officer
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172